Alembic Pharma Gets USFDA Nod for Paroxetine ER Tablets
New Delhi: Alembic Pharmaceuticals Limited has received final approval from the US Food and Drug Administration (USFDA) for its Paroxetine Extended-Release Tablets USP, 12.5 mg, strengthening its portfolio in the US generics market.
The approval pertains to the company’s supplemental Abbreviated New Drug Application (sANDA) for the antidepressant formulation, which is therapeutically equivalent to the reference listed drug Paxil CR Tablets, 12.5 mg, marketed by Apotex Inc.
Paroxetine extended-release tablets are indicated for the treatment of multiple psychiatric conditions, including Major Depressive Disorder (MDD), Panic Disorder (PD), Social Anxiety Disorder (SAD), and Premenstrual Dysphoric Disorder (PMDD), as per the approved labeling.
With this latest approval, Alembic Pharmaceuticals has further expanded its regulatory footprint in the United States. The company now holds a cumulative total of 235 ANDA approvals from the USFDA, comprising 216 final approvals and 19 tentative approvals.
Headquartered in Vadodara, Alembic Pharmaceuticals is a vertically integrated research and development-driven pharmaceutical company with a legacy dating back to 1907. The company is publicly listed and manufactures as well as markets generic pharmaceutical products across global markets.
Alembic’s manufacturing and research facilities are approved by several global regulatory authorities, including the USFDA. In India, the company is among the leading players in the branded generics segment, supported by a strong field force of over 5,500 personnel and a wide portfolio of recognized brands among healthcare professionals and patients.
Also Read: Alembic Pharma Gets 2 USFDA Observations for Karakhadi Injectable Facility
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.